Tumor Cell Therapy Articles & Analysis
25 news found
Expanding the Horizon with Advanced Anti-Tumor APIs Protheragen-ING’s new anti-tumor APIs are a quantum leap forward for cancer therapy. ...
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. The capacity of cancer cells for aerobic glycolysis is 20–30 times greater than that of normal ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on ...
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General ...
ByArdigen
Travera’s unique technology takes advantage of this fluid to screen the response of the live tumor cells against approved anti-cancer therapies. “We are excited to partner with Travera and leverage the application and clinical utility of their incredible technology,” said Mika Newton, CEO of xCures. ...
ByxCures
Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. ...
“Kanya’s experience spans early- to late-stage biotech companies, including gaining product approvals in both liquid and solid tumors, and leading CAR-NK cell therapy programs through the IND process and rapidly demonstrating clinical ...
G-CON, the leader in prefabricated, flexible cleanroom solutions, recently supplied the cleanroom infrastructure for CytoImmune Therapeutics, Inc. (CytoImmune), a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies. G-CON PODs were built in College Station and have been shipped and integrated into CytoImmune’s ...
The data to be presented outline next-generation advancements to Obsidian’s proprietary cytoDRiVE platform technology, which provides a way to precisely control the timing and level of protein function using FDA approved small molecules. Armoring cell therapies with potent cytokines such as IL12 is a promising approach to treating solid ...
Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells ISCT abstract describes scalable, reproducible, cGMP-ready CAR-NK manufacturing process to support planned clinical development of oncology pipeline candidates Senti Bio, a leading gene circuit company, today announced the acceptance of ...
The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. ...
The abstract, titled “Driving anti-tumor activity in solid tumors with controlled arming of allogeneic CAR-NK cells,” details the Company’s efforts to develop gene circuits to arm chimeric antigen receptor natural killer (CAR-NK) cells with multiple cytokines to improve the cytotoxicity and persistence of its ...
IMA401 is the most advanced product candidate in Immatics’ TCR Bispecifics pipeline, called TCER® (T Cell Engaging Receptors), in which one binding region targets MAGEA4/8, a highly prevalent antigen in multiple solid tumors, and the other region engages and activates T cells. ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). ...
“Through this collaboration, our platform will form the basis of a personalized allogeneic cell therapy vision, where any patient can receive a T-cell product for their cancer; a significant step towards our goal of making cell therapies both curative and ...
Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid ...
NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will ...
“We believe our targeted approach, leveraging the unique features of gamma9-delta2 T cells with innovative bispecific antibodies, will deliver novel T cell-based therapies offering advantages over today’s oncology treatments. In addition to the funding raised, the appointments of Nanna, Laia and Joël to our board further ...
“By controlling the expression of armed payloads like CD40L, Obsidian’s cell therapy candidates may have the potential to overcome tumor microenvironment resistance and unlock the power of cell therapy in solid tumors and other ...
Due to its natural in vivo selection of high- affinity TCRs, T-knife’s TCR-T-cell platform has the potential to be a marked improvement over existing TCR technologies in treating solid tumors. ...